Paeds · neurology-neurodisability-and-neuromuscular
Spasticity, dystonia and tone management
Also known as Hypertonicity management · Spasticity management · Dystonia management · Tone management in cerebral palsy · Botulinum toxin therapy · Intrathecal baclofen therapy · Selective dorsal rhizotomy · Upper motor neuron syndrome
Fellowship guide to spasticity, dystonia and tone management in children, centred on cerebral palsy. Covers the Sanger classification of hypertonia into velocity-dependent spasticity and action-induced dystonia with the mixed picture common in cerebral palsy, the goal-directed principle that tone is treated only when it limits function comfort or care, the Modified Tardieu and Modified Ashworth scales and the Gross Motor Function Classification System from GMFCS I to V, the four core modalities of focal botulinum toxin type A with its non-interchangeable products and twelve-week re-injection interval, oral baclofen as a GABA-B agonist that must not be stopped abruptly, intrathecal baclofen with a screening bolus and the medical-emergency withdrawal syndrome, selective dorsal rhizotomy for the ambulant spastic diplegic child, the dystonia pathway from trihexyphenidyl to GPi deep brain stimulation, and the multidisciplinary prevention of contracture hip subluxation scoliosis and pain.
On this page
Study tools
Your progress
Saved on this device.
Practise this topic
Target exams
Red flags
- Intrathecal baclofen withdrawal is a medical emergency: fever, rebound rigidity and spasticity, seizures and rhabdomyolysis can progress to multi-organ failure, so restore the infusion immediately and give enteral baclofen and benzodiazepines
- Never stop oral baclofen abruptly: sudden withdrawal causes seizures, rebound spasticity and hallucinations, so always taper
- Treat the tone only when it is the rate-limiting problem: high tone that does not limit function, comfort, care or hygiene should be observed, not medicalised
- Botulinum toxin products are not interchangeable: onabotulinumtoxinA abobotulinumtoxinA and incobotulinumtoxinA units differ and must never be dose-converted between brands
- Selective dorsal rhizotomy is for the ambulant spastic diplegic child with good selective motor control and minimal dystonia: it fails and may harm the dystonia-dominant or the most severe child
- A child whose pain or function suddenly worsens between injections may have a hip that has subluxed or dislocated, not just tone that has returned: image the hips
Life stages
Care settings
Clinical exam formats
Board mappings
- Recognises that hypertonia in a child is usually an upper motor neuron sign, separates velocity-dependent spasticity from action-induced dystonia, and names cerebral palsy as the commonest cause
- States the goal-directed principle that tone is treated only when it limits function, comfort, care or participation, and names the four core modalities of botulinum toxin, oral baclofen, intrathecal baclofen and selective dorsal rhizotomy
- Names the Gross Motor Function Classification System from GMFCS I to V and uses it to frame prognosis and the choice of tone therapy
- Explains the Sanger framework for hypertonia and distinguishes spasticity from dystonia, rigidity and mixed tone using the Modified Tardieu Scale and a careful history of provocation and overflow
- Matches the tone modality to the goal and the phenotype: focal botulinum toxin for focal spasticity, oral then intrathecal baclofen for generalised spasticity, selective dorsal rhizotomy for the ambulant spastic diplegic child, and a dystonia pathway from trihexyphenidyl to GPi deep brain stimulation
- Runs the multidisciplinary team that prevents contracture, hip subluxation, scoliosis and pain, and manages the intrathecal baclofen withdrawal syndrome as a medical emergency
- The Sanger classification of hypertonia into velocity-dependent spasticity and action-induced dystonia, with the mixed picture common in cerebral palsy
- The four core modalities of botulinum toxin type A, oral baclofen, intrathecal baclofen and selective dorsal rhizotomy with their indications and their key dangers
- The goal-directed principle that tone is treated only when it limits function, comfort, care or hygiene, and the GMFCS levels I to V that frame prognosis and therapy choice
- Assesses the child with cerebral palsy, separates the spastic from the dystonic phenotype, sets SMART goals with the family, and chooses the modality that matches the goal
- Manages botulinum toxin injection cycles with correct non-interchangeable dosing and a twelve-week minimum interval, and counsels on the intrathecal baclofen withdrawal syndrome
- Coordinates the multidisciplinary surveillance for hip subluxation, scoliosis, contracture and pain across childhood and into transition
- Level 1: Recognition that high tone in a child is usually an upper motor neuron sign, that spasticity and dystonia differ, and that cerebral palsy is the commonest cause
- Level 2: Application of the goal-directed principle and the four core modalities with the Modified Tardieu Scale and the GMFCS levels
- Level 3: Coordination of lifelong multidisciplinary care, the intrathecal baclofen and selective dorsal rhizotomy pathways, and the prevention of musculoskeletal complications
- Spasticity as a velocity-dependent increase in tonic stretch reflexes and dystonia as involuntary sustained or intermittent muscle contraction causing twisting postures and overflow, with the mixed picture common in cerebral palsy
- The four core tone modalities of botulinum toxin type A, oral baclofen, intrathecal baclofen and selective dorsal rhizotomy with their indications and key dangers
- The goal-directed principle that tone is treated only when it limits function comfort or care, and the prevention of contracture hip subluxation scoliosis and pain
- Structured assessment of a child with cerebral palsy using the Modified Tardieu Scale and the GMFCS, separating spasticity from dystonia
- Choice of the tone modality matched to the goal and the phenotype with the botulinum toxin and intrathecal baclofen and selective dorsal rhizotomy evidence
- Communication with the family on goal setting, the intrathecal baclofen withdrawal danger, and the lifelong multidisciplinary plan
- Spasticity and dystonia in cerebral palsy as upper motor neuron signs, with the Sanger classification of hypertonia and the GMFCS levels I to V
- The four core tone modalities with the AAN evidence-based practice parameter and the botulinum toxin and selective dorsal rhizotomy trial evidence
- The goal-directed principle and the multidisciplinary prevention of musculoskeletal complications across childhood
- Recognition of the child with hypertonia, separation of spasticity from dystonia, and identification of the tone that limits function comfort or care
- Stepwise management from focal botulinum toxin to oral and intrathecal baclofen to selective dorsal rhizotomy, matched to the goal and the phenotype
- Coordination of the multidisciplinary team and the management of the intrathecal baclofen withdrawal syndrome as an emergency
- Canadian approach to cerebral palsy tone management with the goal-directed principle and the four core modalities
- The selective dorsal rhizotomy pathway for the ambulant spastic diplegic child and the intrathecal baclofen pathway for the severe generalised child
- Coordination of lifelong multidisciplinary care and the prevention of contracture hip subluxation scoliosis and pain
Overview & Definition
A child whose arm draws up and whose hand clenches when they reach for a toy, or whose legs stiffen and scissor the moment they try to stand, is showing you hypertonia, and the paediatric job is to decide whether that tone is worth treating and how. Hypertonia is the abnormally increased resistance to an externally imposed movement about a joint, and in a child it is almost always an upper motor neuron sign. Cerebral palsy is the commonest cause, but the same tone problems follow spinal cord injury, traumatic brain injury, and a handful of metabolic and genetic disorders, and the principles of management carry across them all. [1][2]
The single idea that governs the whole topic is that tone is treated only when it limits function, comfort, care or participation. A stiff leg that lets a child stand and transfer is an asset, not a target; a stiff adductor that defeats nappy changing and hygiene is a target. The fellowship candidate who reaches for this principle first, and matches the modality to the goal, will answer every tone question well. [1]
Four modalities carry the workload: focal botulinum toxin type A for the few troublesome muscles, oral baclofen for generalised spasticity, intrathecal baclofen for the severe generalised or dystonic child, and selective dorsal rhizotomy for the ambulant spastic diplegic child. The two phenotypes of spasticity and dystonia decide which one fits, and the Gross Motor Function Classification System decides how ambitious the functional goal can be. [3][6]
References12ShowHide
- [1]Delgado MR, Hirtz D, Aisen M, et al. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology, 2010.PMID 20101040
- [2]Shaunak M, Kelly VB Cerebral palsy in under 25 s: assessment and management (NICE Guideline NG62). Arch Dis Child Educ Pract Ed, 2018.PMID 29056589
- [3]Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol, 1997.PMID 9183258
- [4]Fehlings D, Novak I, Berweck S, et al. Botulinum toxin assessment, intervention and follow-up for paediatric upper limb hypertonicity: international consensus statement. Eur J Neurol, 2010.PMID 20633178
- [5]Molenaers G, Fagard K, Van Campenhout A, Desloovere K Botulinum toxin A treatment of the lower extremities in children with cerebral palsy. J Child Orthop, 2013.PMID 24432099
- [6]McLaughlin J, Bjornson K, Temkin N, et al Selective dorsal rhizotomy: meta-analysis of three randomized controlled trials. Dev Med Child Neurol, 2002.PMID 11811645
- [7]Tedroff K, Hägglund G, Miller F Long-term effects of selective dorsal rhizotomy in children with cerebral palsy: a systematic review. Dev Med Child Neurol, 2020.PMID 31342516
- [8]Albright AL, Cervi A, Singletary J Intrathecal baclofen for spasticity in cerebral palsy. JAMA, 1991.PMID 1999883
- [9]Albright AL, Barry MJ, Painter MJ, et al. Infusion of intrathecal baclofen for generalized dystonia in cerebral palsy. J Neurosurg, 1998.PMID 9420075
- [10]Eek MN, Olsson K, Lindh K, et al. Intrathecal baclofen in dyskinetic cerebral palsy: effects on function and activity. Dev Med Child Neurol, 2018.PMID 29148568
- [11]Monbaliu E, de Cock P, Ortibus E, et al. Clinical patterns of dystonia and choreoathetosis in participants with dyskinetic cerebral palsy. Dev Med Child Neurol, 2016.PMID 26173923
- [12]Harvey AR, Baker LB, Reddihough DS, et al. Trihexyphenidyl for dystonia in cerebral palsy. Cochrane Database Syst Rev, 2018.PMID 29763510